EGFR-TKI治疗肺腺癌的疗效与血清肿瘤标志物的相关性  

Correlations between EGFR Tyrosine Kinase Inhibitor and Serum Level of Tumor Marker in Lung Adenocarcinoma

作　　者：潘金兵[1] 侯宇虹[2] 钱皓瑜[1] 

机构地区：[1]河南省人民医院呼吸科,郑州450003 [2]郑州大学第一附属医院急诊科

出　　处：《肿瘤防治研究》2012年第5期515-518,共4页Cancer Research on Prevention and Treatment

摘　　要：目的探讨表皮生长因子受体酪氨酸激酶抑制剂(epidermal growth factor receptor tyrosine ki-nase inhibitor,EGFR-TKI)对肺腺癌的疗效和血清肿瘤标志物间的关系。方法回顾分析48例应用EGFR-TKI治疗的晚期肺腺癌患者的临床特征、生存时间和治疗前血清肿瘤标志物水平的相关性。结果 EGFR-TKI治疗后有效率为58.3%,控制率为65.6%;中位生存时间为13.2月。统计学分析显示:吸烟史、血清CEA和CA19-9水平与EGFR-TKI的疗效相关(P<0.05);治疗前血清CEA,CA19-9水平高者有着更高的治疗有效率、控制率和更长的生存期(P<0.05)。结论 EGFR-TKI治疗前血清CA19-9和CEA的水平对预测EGFR-TRI对肺腺癌患者的疗效有参考价值。Objective To investigate the relationship between epidermal growth factor receptor tyrosine kinase inhibitors（EGFR-TKI） treatment effects and serum tumor markers in lung adenocarcinoma.MethodsForty-eight patients with advanced lung adenocarcinoma were treated with EGFR-TKI.The clinical features,survival time and the level of serum tumor markers for the patients before and after treatment were retrospectively analyzed.Results After EGFR-TKI treatment,the RR was 58.3% and DCR was 65.6% in lung adenocarcinoma;and median survival time was 13.2 months.Responses correlated significantly with smoking history and level of CEA or CA19-9 in serum（P0.05）.Patients with higher level of serum CEA and CA19-9 had higher disease control rate and longer survival（P0.05）.Conclusion Serum CA19-9 or CEA level can predict the response of EGFR-TKI to lung adenocarcinoma.

关 键 词：表皮生长因子受体酪氨酸激酶抑制剂 肺腺癌 肿瘤标志物 

分 类 号：R734.2[医药卫生—肿瘤]